Close Menu

Station X

Epic Sciences will incorporate Station X's GenePool data-analysis platform into its collaborations to develop CTC-based companion diagnostics. 

Station X is using Qubole's cloud-based platform to power GenePool, its software-as-a-service solution for analyzing genomic and medical data.

Qiagen said this week that it plans to launch the CLC Cancer Research Workbench, a customizable bioinformatics solution that will offer flexible, cancer-specific analysis workflows in April 2014.

Customers of GenePool, Station X's newly launched software for genomic and clinical data management and analysis, said this week that factors such as its ease of use, ready access to cloud infrastructure, and its ability to analyze both large and small numbers of samples make it

Station X has launched GenePool, a cloud-based software application to manage, analyze, and communicate genomic and clinical information. Users can analyze sequence information from both DNA and RNA to identify biomarkers.

Station X has launched GenePool, a cloud-based software application to manage, analyze, and communicate genomic and clinical information. Users can analyze sequence information from both DNA and RNA to identify biomarkers.

Increasing activity from sequencing vendors and other new players, as well as a flurry of activity around clinical data analysis software and the commercialization of a number of open source tools were the key trends in the bioinformatics community in 2012.

NEW YORK (GenomeWeb News) – Station X, a Redwood City, Calif.-based bioinformatics firm, has closed a second round of equity financing led by Runa Capital that included follow-on commitments from existing investors including Genomic Health.

After wrapping up a recent fundraising round involving an unnamed investor, informatics startup Station X is preparing to launch its first product for the clinical research market — a tool focused on biomarker discovery from genomic data, BioInform learned this week.

By Uduak Grace Thomas
Genomic Health is beefing up its informatics portfolio as part of its efforts to use next-generation sequencing for biomarker discovery and diagnostic testing.

Pages

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.